2. Search Result
Search Result
Results for "

PET tracer

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139048
    Fluoroethylnormemantine

    		iGluR Neurological Disease
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine
  • HY-139048A
    Fluoroethylnormemantine hydrochloride

    		iGluR Neurological Disease
    Fluoroethylnormemantine hydrochloride, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [ 18F]-Fluoroethylnormemantine hydrochloride can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine hydrochloride exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects .
    Fluoroethylnormemantine hydrochloride
  • HY-101184
    T807
    1 Publications Verification

    AV-1451

    		 Tau Protein Neurological Disease
    T807 a novel tau positron emission tomography (PET) tracer.
    T807
  • HY-120717
    VU6001966

    		mGluR Others
    VU6001966 (compound 15m) is a potent and cross the blood-brain barrier mGlu2 (metabotropic glutamate receptor 2) negative allosteric modulator with IC50s of 78 nM and >30 µM for mGlu2 and mGlu3, respectively. VU6001966 can serve as an mGlu2 PET tracer .
    VU6001966
  • HY-156982
    Parpi

    		Others Cancer
    Parpi is a PET radioactive tracer with low lipotropy. Parpi can be used as a tumor imaging agent .
    Parpi
  • HY-163075
    SYB4

    		Others Others
    SYB4 (compound 5) is a PET tracer which suitable for imaging the Sigma-2 Receptor in the brain of nonhuman primates .
    SYB4
  • HY-101186
    MK-6240
    1 Publications Verification

    		 Others Neurological Disease
    MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
    MK-6240
  • HY-147173
    FAPI-74

    		FAP Cancer
    FAPI-74 is a PET (positron emission tomography) tracer targeting the fibroblast activation protein (FAP). FAPI-74 can be used for FAP-positive tumor research .
    FAPI-74
  • HY-153550
    PSMA-1007

    		PSMA Others
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging .
    PSMA-1007
  • HY-111514
    4-(6-Bromo-2-benzothiazolyl)benzenamine

    		Oxidative Phosphorylation Amyloid-β Neurological Disease
    4-(6-Bromo-2-benzothiazolyl)benzenamine is a β-amyloid PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.
    4-(6-Bromo-2-benzothiazolyl)benzenamine
  • HY-110141
    ABP688

    		mGluR Others
    ABP688 is a high affinity human mGluR5 antagonist with anKi of 1.7 nM. Radioisotope-labeled ABP688 can be used as a PET tracer for clinical imaging of the mGlu5 receptor .
    ABP688
  • HY-125399
    PSMA-11

    HBED-CC-PSMA

    		 PSMA Cancer
    PSMA-11 is a positron emission tomography (PET) tracer. PSMA-11 detects prostate cancer relapses and metastases by binding to the extracellular domain of prostate-specific membrane antigen (PSMA) .
    PSMA-11
  • HY-126226
    MK-6240 Precursor

    		Others Cancer
    MK-6240 Precursor (6e) is the synthetic precursor of (18)F]-MK-6240. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
    MK-6240 Precursor
  • HY-42110
    Deschloroclozapine
    Maximum Cited Publications
    35 Publications Verification

    		 mAChR Neurological Disease
    Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [ 11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .
    Deschloroclozapine
  • HY-42110A
    Deschloroclozapine dihydrochloride
    Maximum Cited Publications
    35 Publications Verification

    		 mAChR Neurological Disease
    Deschloroclozapine dihydrochloride, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with Ki of 6.3 and 4.2 nM, respectively. [ 11C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .
    Deschloroclozapine dihydrochloride
  • HY-128642
    FAPI-2

    		FAP Cancer
    FAPI-2 is a quinoline-based therapeutic ligand targeting fibroblast activator protein. FAPI-2, a ligand for the synthesis of 68Ga-FAPI-2, is a PET tracer. FAPI-2 is a fibroblast activating protein (FAP) inhibitor that can be used in cancer research .
    FAPI-2
  • HY-141464
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH

    Fmoc-Asn(Ac3AcNH-beta-Glc)-OH

    		 Amino Acid Derivatives Cancer
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .
    Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH
  • HY-119190
    PF-06445974

    		Phosphodiesterase (PDE) Neurological Disease
    PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 <1 nM. The IC50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study .
    PF-06445974
  • HY-156102
    c-ABL-IN-5

    		Bcr-Abl Neurological Disease
    c-ABL-IN-5 is a selective c-Abl inhibitor with neuroprotective effects. c-ABL-IN-5 has blood-brain barrier penetrability, metabolic stability and good pharmacokinetic properties. When c-ABL-IN-5 is labeled with [18F] (compound [18F]3), it can be used as a tracer to evaluate disease-modifying efficacy by complementary positron emission tomography (PET). c-ABL-IN-5 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .
    c-ABL-IN-5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: